Status:
COMPLETED
Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
BEIJING HOLLEY-COTEC PHARMACEUTICALS CO. LTD.
Conditions:
Malaria
Eligibility:
All Genders
3-59 years
Phase:
PHASE2
PHASE3
Brief Summary
The aim of the study is to determine whether piperaquine plus dihydroartemisinin (DHA-PQ) is as effective, and better tolerated, than sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ), when used for ...
Detailed Description
There is evidence from several studies that in areas where the transmission of malaria is seasonal, the use of IPT can reduce substantially the incidence of clinical malaria in children under the age ...
Eligibility Criteria
Inclusion
- signed consent from a parent
- age 3-59 months at enrolment
- no history of allergy to study drugs
- no chronic illness
Exclusion
- history of allergy to study drugs
- intention to move away from the study area before the end of 2009
- any chronic illness
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT00941785
Start Date
July 1 2009
End Date
December 1 2009
Last Update
March 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRSS
Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso, BP545